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non-inferior to enoxaparin/VKA for recurrent VTE (HR: 1.12, 95%CI 0.75-1.68) and 
demonstrated a significant reduction in major bleeding (HR: 0.49, 95%CI 0.31-0.79, 
P= 0.003). STUDY QUESTION: What is the incremental cost/QALY gained, from a 
Canadian provincial government perspective, for rivaroxaban compared to LMWH/
VKA for treatment of PE, over a 5 year horizon? Methods: A Markov model was 
developed. Patients entered the model with an index PE and required 3, 6 or 12 
months of treatment. Patients were exposed to treatment-specific risks of recurrent 
VTE and bleeding events, and associated mortality and long-term complications. 
Clinical inputs were from EINSTEIN-PE and published literature. Economic inputs 
were from publically available Canadian sources. Consistent with EINSTEIN-PE, 
a reduction in hospital length of stay was included for admitted patients treated 
with rivaroxaban. Utility inputs were from published literature. Extensive sensi-
tivity analyses were conducted. Results: Rivaroxaban dominated LMWH/VKA at 
all treatment durations examined. In patients appropriate for 3, 6 and 12 months 
treatment, rivaroxaban demonstrated per patient cost savings of $629, $561 and $341 
($CAN), and QALY gains of 0.002, 0.004 and 0.005, respectively. Findings were robust 
to sensitivity analysis. ConClusions: Rivaroxaban is a cost-effective treatment for 
PE, dominating LMWH/VKA for patients requiring up to 12 months treatment. The 
positive clinical and economic profiles of rivaroxaban together make it a valuable 
treatment option for Canadian PE patients and payers.
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Assessing The eConomiC Burden And heAlTh CAre uTilizATions 
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objeCtives: To examine the economic burden and health care utilizations of 
post-traumatic stress disorder (PTSD) after unstable angina (UA) in the U.S. vet-
eran population. Methods: A retrospective database analysis was conducted using 
the Veterans Health Administration Medical SAS datasets (01OCT2007-30SEP2012). 
Adult patients with a PTSD diagnosis (International Classification of Disease, 9th 
Revision, Clinical Modification [ICD-9-CM] code: 309.81) were identified. The first 
PTSD diagnosis date was designated as the index date. UA diagnosis (ICD-9-CM 
codes: 411.1, 411.81, 411.89) was required 1 month before the first PTSD diagnosis 
during the baseline period. A comparator group was created by identifying patients 
without PTSD using 1:1 propensity score matching, with covariates including age, 
region, gender, index year and baseline Charlson comorbidity index score. A ran-
domly-chosen index date for the comparator group reduced selection bias. One-
year continuous enrollment was required before and after the index date for both 
groups. Health care costs and utilizations were compared between the disease and 
comparator groups in the matched sample. Results: After 1:1 matching, a total 
of 341 patients were matched from each group with well-balanced baseline char-
acteristics. Patients diagnosed with UA-induced PTSD had significantly more inpa-
tient admissions (21.41% vs. 2.64%, p< 0.0001) and emergency room (ER) (32.84% vs. 
10.56%, p< 0.0001), physician office (99.12% vs. 78.30%, p< 0.0001), outpatient (99.12% 
vs. 79.77%, p< 0.0001) and pharmacy visits (97.07% vs. 82.99%, p< 0.0001). Higher 
health care utilizations translated to higher costs for UA-induced PTSD patients, 
including inpatient ($4,406 vs. $731, p< 0.0001), ER ($349 vs. $82, p< 0.0001), physician 
office ($5,934 vs. $2,304, p< 0.0001), outpatient ($6,679 vs. $2,492. P< 0.0001), pharmacy 
($1,146 vs. $570, p< 0.0001) and total costs ($12,231 vs. $3,793, p< 0.0001), relative to 
those in the comparison group. ConClusions: The study results suggest that the 
economic burden and health care utilizations were significantly higher for patients 
diagnosed with PTSD after UA diagnosis versus those without.
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CosT-uTiliTy AnAlysis of AngioTensin-ConVerTing enzyme inhiBiTor-
BAsed TreATmenT ComPAred To ThiAzide diureTiC-BAsed TreATmenT 
in An elderly hyPerTensiVe PoPulATion Considering mAjor 
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objeCtives: Both Thiazide-diuretics and angiotensin-converting enzyme inhibi-
tors (ACEI) have similar efficacy in treating hypertension in elderly though ACEI is 
costlier. Using diuretic is associated with increased risk of developing new-onset 
diabetes compared to ACEI. To date evidence is lacking on the cost-effectiveness 
(CE) of ACEI compared to diuretic-based treatment considering diabetes develop-
ment as part of treatment. This study aims to determine the CE of ACEI compared 
to thiazide-diuretic based treatment of hypertension in the elderly in an Australian 
context. Methods: A cost-utility analysis was undertaken using real data from the 
Second Australian National Blood Pressure Study, a randomized clinical trial com-
paring diuretic-based versus ACEI-based treatment in an elderly (age ≤ 65yr) hyper-
tensive population over a median 4.1-year period. Three models were used: 1) ‘model 
A’ includes all study subjects without considering diabetes at any stage (n= 6072); 
2) ‘model B’ includes diabetes-free subjects at the start (n= 5616); and 3) ‘model C’ 
includes subjects with diabetes at the start (n= 422) of the trial. One-way and proba-
bilistic sensitivity analyses were performed to assess the uncertainty. Results: CE 
analyses showed that in model A, the quality-adjusted life-year (QALY) gained was 
0.004 per person for ACEI-based treatment compared to diuretic-based treatment 
and the incremental cost-effectiveness ratio (ICER) per QALY gained was AUD 62,472. 
For model B, there was 0.009 QALY’s gained per-person and the ICER per QALY gained 
being AUD 29,535. Model C was a dominant strategy (cost-saving). On sensitivity 
analysis, the ICER per QALY gained for model B and C were always below AUD50,000; 
whereas for model A the probability was 25%. ConClusions: Initial treatment with 
diuretic-based treatment of hypertension in the elderly is less expensive, but con-
sidering the potential enhanced likelihood of development of diabetes in addition 
to costs of cardiovascular disease, ACEI-based treatment might be a cost-effective 
and safer alternative in this patient group.
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objeCtives: To demonstrate the use of value of information analyses to esti-
mate the value of the prospective Potential of r-tPA for Ischemic Strokes with Mild 
Symptoms (PRISMS) trial studying recombinant tissue plasminogen activase (r-tPA) 
for the treatment of mild stroke patients. Methods: We programmed a value 
of information decision model comparing the outcomes of mild stroke patients 
who were treated vs. not treated with r-tPA. We modeled specific stroke severity 
health states based on modified Rankin scores using Markov modeling techniques. 
Preliminary estimates of r-tPA effectiveness in mild patients were derived from a 
subset of International Stroke Trial-3 patients. Utility and cost inputs were derived 
from other published sources. Model simulations assessed the expected value of 
the prospective trial and the expected value of reducing uncertainty in key trial 
estimates. Results: At a societal willingness-to-pay per quality-adjusted life year 
of $100,000, the PRISMS trial’s expected value of sample information was approxi-
mately $1.1 billion. Uncertainty reduction in the absolute difference in nondisabled 
patients (mRS 0-1) between strategies had the greatest expected value at $963 mil-
lion, followed by uncertainty reduction in the mRS distribution of r-tPA patients at 
$466 million. Reducing uncertainty in costs, long-term life expectancy, and utility 
measures did not offer any additional societal value. ConClusions: Our analysis 
suggests a prospective trial of r-tPA for mild stroke patients seems justified based 
on the potential value of research. The trial’s expected benefits could be compared 
to those of other competing research proposals when prioritizing future research 
funding.
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objeCtives: Little is known on how pulmonary arterial hypertension (PAH) may 
impact worker productivity. The objective of this study was to estimate indirect 
costs of PAH in an employed population. Methods: Data came from Truven’s 
MarketScan Health and Productivity Management database. PAH workers were 
identified based on having > 2 medical claims for primary pulmonary hyperten-
sion (ICD-9 code:416.0), and either one claim for right heart catheterization or one 
claim of echocardiogram. The first medical claim during this period served as in 
the index date with 6 months prior to this event as baseline and 12 months post as 
follow-up period. Three non-PAH employees were matched to each PAH worker on 
age, gender, census region, and plan type. Annual productivity loss was calculated 
as a sum of absenteeism and short term disability (STD) in the follow-up year and 
derived by multiplying the reported days off work times the industry-specific aver-
age daily wage rate obtained from the 2012 US Department of Labor. Results: 72 
and 187 PAH workers met the absentee and STD eligibility benefits. The average age 
was approximately 50 years; over 52% were females, majority from the south region 
and enrolled in a preferred provider organization type health plan. Approximately 
90% of PAH patients held a full-time position, majority were either salaried or a 
non-Union hourly wage earner and employed in a manufacturing or transportation 
type of industry. The average daily wage rate was estimated at $191.20. In one-year, 
PAH workers on average had significantly higher absentee (33 vs. 23.6) and STD days 
(29.6 vs. 7.3) compared to the control group, respectively. Based on the daily wage 
rate the average annual productivity loss was $8,686 vs. $4,822 for PAH and non-PAH 
employees. ConClusions: Productivity loss among PAH workers was found to be 
44% higher than non-PAH employees.
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objeCtives: Heart failure (HF) patients are frequently hospitalized, resulting in 
reduced quality of life and increased health expenditures. This study estimates 
recent rates of hospitalizations among systolic HF patients in the US. Methods: 
This retrospective study used a large, nationally representative commercial data-
base. Adult patients aged 18-64 years with ≥ 1 inpatient or ≥ 2 outpatient diagnoses 
of systolic HF (ICD-9-CM 428.2x, 428.4x) in 2008-2013 with ≥ 12-months of claims 
data prior to and ≥ 1-month claims data after the first systolic HF diagnosis were 
included. Number of hospitalizations per patient-year of all-cause hospitalizations 
and hospitalizations with HF as a discharge diagnosis during the entire follow up 
were summarized. Hospitalization rates after patients had 1, 2, and 3 all-cause 
hospitalizations were also reported. Results: A total of 25,830 patients (mean 
age= 54 (SD 8.6); 63% male; 34% hypertension; 26% diabetes; 21% dyslipidemia; 20% 
arrhythmias) met the study criteria, with a mean follow up of 19 (SD 14.7) months. 
67.8% of patients were hospitalized during the follow up, 29.3% had 2+, 16.1% had 
3+ hospitalizations. During the entire study period following the systolic HF diag-
nosis, the mean numbers of hospitalizations per patient-year were 1.63 (SD= 2.62) 
for all-cause and 1.22 (SD= 2.16) for HF hospitalizations. After the first all-cause 
hospitalization, the mean number of subsequent hospitalizations per patient-year 
was 1.02 (SD= 2.17) for all-cause and 0.50 (SD= 1.45) for HF hospitalizations. The 
annualized rates for subsequent hospitalizations were higher after the 2nd and 3rd 
all-cause hospitalizations. ConClusions: From the time of diagnosis with systolic 
HF, hospitalizations are common and some patients experience multiple hospi-
talizations per year. The risk of subsequent hospitalizations increased in subjects 
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with a history of recurrent hospitalizations. Interventions targeted at preventing 
HF hospitalizations would be beneficial.
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Fanourgiakis J.1, Simantirakis E.1, Kanoupakis E.1, Chrysostomakis S.1, Maniadakis N.2, 
Kourlaba G.3, Vardas P.1
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3National and Kapodistrian University of Athens School of Medicine, Athens, Greece
objeCtives: The objective of the study is to estimate the follow up cost and its com-
ponents in patients subjected to pacemaker (PM) and implantable cardioverter-defi-
brillator (ICD) implantation. Methods: A single-center, prospective, study which 
was conducted for one year’s reriod. In total, 464 consecutive patients were recruited 
(370 were subjected to PM implantation, from which 240 initials, 130 replacements 
and 94 to ICD implantation, from which 80 initials, 14 replacements). Resource 
data were assessed at patients’ enrolment in the study and at 6th and 12th months 
of patients’ follow-up. Then, the annual patients’ follow up costs were calculated 
using the bottom-up approach. Results: The annual follow up cost for the patients 
who were subjected to PM implantation (initial or replacement) was found to be: 
The mean direct health care cost (outpatient visits, hospitalizations, medication 
use and the cost of laboratory and imagining diagnostic examinations) was € 1.386 
(€ 1.069-€ 1.962). The mean direct non-health care cost was € 359 (€ 207-€ 551). Finally 
the mean indirect cost was € 71 (€ 70-€ 72). The mean (95% confidence interval) total 
annual follow-up cost for the patients who were subjected to PM implantation was 
€ 1.816 (€ 1.433– € 2.421). The annual follow up cost for the patients were subjected 
to ICD implantation (initial or replacement) was found to be: The mean direct health 
care cost (outpatient visits, hospitalizations, medication use and the cost of labo-
ratory and imagining diagnostic examinations) was 2.279 (1743-3.081). The mean 
direct non-health care costs was € 173 (€ 11-€ 386). Finally the mean indirect cost 
was € 367 (€ 72-€ 802). The mean (95% confidence interval) total annual follow-up 
cost for the patients who were subjected to ICD implantation was € 2.819 (€ 2.115–€ 
3.703). ConClusions: The study provides unique data regarding the follow up 
cost and its separate components of patients with CRMDs in Greece. Moreover the 
findings indicate a low annual follow-up cost.
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ChroniC heArT fAilure: A CAnAdiAn AssessmenT
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objeCtives: Limited evidence exists on the burden of chronic heart failure (CHF) 
in terms of reduced vs. preserved ejection fraction (HFrEF vs. HFpEF) and NYHA 
classification. This study aims to determine health care resource utilization asso-
ciated with CHF, both for HFrEF (≥ 45%) and HFpEF (< 40%) and according to NYHA 
class. Methods: Retrospective analysis of a longitudinal population-based medical 
records database from southwestern Ontario was conducted. Records contain chart-
abstracted information such as diagnosis, physician visits and consultation notes. 
Data of adult patients with CHF diagnosed between Jan 1st, 2005 and Sept 31st, 2012 
with at least 1 year follow-up were included. Health care resources consumed by 
patients were identified in terms of hospitalizations, physician and emergency room 
visits and medical procedures. Data reported as mean values. Results: Records 
of 8,983 patients were included: 39% with HFrEF, 49% with HFpEF and 12% with an 
ejection fraction between 40-45%. The median follow-up duration was 51.6 months. 
Most patients were in NYHA class II (30%) or class III (34%) followed by class I (22%) 
and class IV (14%). In comparison to the HFpEF cohort, total hospitalizations (3.0 vs. 
4.2); including CHF hospitalizations (1.6 vs. 1.9), ER visits (2.1 vs. 3.1), GP visits (5.5 
vs. 6.1), specialist visits (3.0 vs. 3.2), lab tests (5.8 vs. 7.7) and medical procedures 
(3.9 vs. 4.1) were numerically higher for the HFrEF cohort. Among patients in NYHA 
class II-IV (N= 7006), hospitalizations (total: 4.5; CHF-related: 2.1) and lab tests (7.7) 
were numerically higher for class IV patients as was the frequency of GP visits (7.1) 
for class III patients. ER and specialist visits and medical procedures were similar 
across all NYHA classes. ConClusions: In a real-world Canadian setting, patients 
with HFrEF and those in NYHA class III-IV seem to experience greater resource use 
which is consistent with the existing literature.
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objeCtives: The objective of the present study is to estimate the procedure (or 
implantation) cost, which includes: the human resources cost, the implant and 
the supplies cost and the total hospitalization cost which includes: the procedure 
cost, the hospitalization cost, the laboratory and imaging diagnostic examination 
cost and the indirect cost, in patients subjected to pacemaker (PM) and implantable 
cardioverter-defibrillator (ICD) implantation. Methods: A single-centre, prospec-
tive study was conducted for one year’s period. In total, 464 consecutive patients 
were recruited (370 were subjected to PM implantation initial or replacement and 94 
to ICD implantation initial or replacement). Resource data were assessed at patients’ 
enrolment in the study as well as during the procedure of implantation. Then, the 
components of the procedure cost and total hospitalization cost were calculated 
using the bottom-up approach. Results: The mean (95% confidence interval) pro-
cedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1.803 (€ 1.758–€ 1.858) and 
€13.521 (€ 13.153–€13.892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3.926 (€ 3.711–€ 4.167) for PM and € 17.764 (€ 16.852–€ 18.692) for 
ICD. ConClusions: These data revealed that although these devices are associ-
ated with a relatively high upfront cost, the total implantation cost for the society 
is relatively low compared with other countries. Therefore, implantation of such 
devices should be encouraged since these devices reduce the morbidity and mortal-
ity without a high economic burden to society.
CArdioVAsCulAr disorders – Patient-reported outcomes & Patient Prefer-
ence studies
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imPACT of ProVider mAilings on mediCATion AdherenCe in mediCAre 
PArT d memBers
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objeCtives: Medication non-adherence is associated with worsening health out-
comes and higher medical costs. This study assessed the impact of a prescriber 
mailing intervention on adherence among 802,355 members enrolled in Medicare 
Part D prescription drug plans offered by a pharmacy benefit manager. Methods: 
Non-adherent members in three drug classes – oral antidiabetics, statins and one 
class of antihypertensives (RAS antagonists) – were identified if their specific drug 
class proportion of days covered (PDC) was < 80% in a 12-month baseline period 
(2010Q4-2011Q3). Letters were mailed to their prescribers suggesting they discuss 
potential adherence barriers with their patients. Post-mailing PDC was calculated 
during a 12-month follow-up period after the mailing date. Members were included 
if they were age 18+, had 2 or more fills within the drug class, and were continu-
ously enrolled in the prescription drug plan during the baseline and follow-up peri-
ods. A historical control cohort was constructed using the same eligibility criteria 
as applied to the intervention cohort but no letter was mailed to the prescribing 
physicians. Multivariate logistic regression was used to model post-mailing adher-
ence (PDC≥ 80%), adjusting for age, gender, zip code level income, education and 
race variables. Analyses were conducted separately for each drug class. Results: 
Final analyzable members included 21,044 (Intervention= 10,707; Control= 10,337) 
for antidiabetics, 106,829 (Intervention= 53,957; Control= 52,872) for statins, and 
73,560 (Intervention= 36,706; Control= 36,854) for RAS antagonists. The baseline 
PDCs between the intervention and control cohorts were not statistically differ-
ent for all the three drug cohorts. Adjusted logistic regression results indicate the 
prescriber mailing was associated with significant adherence improvement, odds 
ratio (OR) 1.11 (95% confidence interval [CI], 1.05-1.18), OR 1.16 (95% CI, 1.13-1.19), 
and OR 1.07 (95% CI, 1.03-1.10) within the antidiabetic, statin and RAS antagonist 
drug classes, respectively. ConClusions: Health plans should consider utilizing 
prescriber mailings in efforts to improve medication adherence for chronic diseases.
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drug ComPliAnCe Among hyPerTensiVe PATienTs: A QuesTionnAire 
BAsed sTudy ConduCTed in A TerTiAry CAre hosPiTAl in PAkisTAn
Ahmad M., Bukhari S.A., Pervaiz F., Akhtar M.
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objeCtives: To analyze patient compliance towards their prescribed medication 
and to evaluate the patient knowledge regarding use of drugs. Methods: The study 
was conducted in a tertiary care hospital in Pakistan. A random sample of 200 
patients was selected. The questionnaire was administered by trained interviewers 
in the Urdu language for ease of understanding by the patient. The questionnaire 
extracted information regarding patient demographics, life style (smoking, drink-
ing, physical activities), awareness about and characteristics of hypertension and 
anti-hypertensive treatment and factors that, in the patient’s views, encouraged or 
discouraged the patient’s drug taking behavior. Results: According to analysis, 81% 
patients were from urban areas and 19% patients were from rural areas. Most (71%) 
of the patients belonged to the age group of 40-50 years. Majority of the affected 
persons were male i.e. 70%, whereas females were 30%. The patients with history of 
CVS disorders in their families were 36%. It was found that 36% of the patients were 
smokers, 2% were drinkers and 75% had no physical activity in routine. The patients 
went for regular follow up of their blood pressure were 38.5% and 53% of the patients 
had regular lab tests during their treatment. It was found that 74.5% of patients used 
to take medication on time while 64% stopped their medication when they felt bet-
ter. The major reason (27.5%) for not taking medication was found to be the use of 
alternative medicines while 60% patients tried to clarify their doubts about therapy. 
Majority of patients (81.5%) followed precautionary measures, 21% patients used 
different reminders and 30.5% patients had difficulty in taking their medication. 
On felling worse 40% of the patients stopped taking medication. ConClusions: 
There is need for educational intervention and patient counseling to understand 
the importance of compliance for this disease.
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objeCtives: Single pill combinations (SPC) are associated with improved adher-
ence and persistence in hypertensive (HTN) populations. The evidence is not 
available for three drug SPC Exforge HCT. This study investigated if Exforge HCT 
is associated with improved 12-month persistence and adherence in adult hyper-
